128 related articles for article (PubMed ID: 35245410)
41. Proton Pump Inhibitors, But Not H2-receptor Antagonists, Are Associated With Incident Fractures Among Kidney Transplant Recipients.
Lyu B; Jorgenson MR; Hansen KE; Djamali A; Astor BC
Transplantation; 2020 Dec; 104(12):2609-2615. PubMed ID: 32058466
[TBL] [Abstract][Full Text] [Related]
42. Risk of circulatory diseases associated with proton-pump inhibitors: a retrospective cohort study using electronic medical records in Thailand.
Pannoi T; Promchai C; Apiromruck P; Wongpraphairot S; Dong YH; Yang CC; Pan WC
PeerJ; 2024; 12():e16892. PubMed ID: 38371380
[TBL] [Abstract][Full Text] [Related]
43. Helicobacter gastritis induces changes in the oxyntic mucosa indistinguishable from the effects of proton pump inhibitors.
Kumar KR; Iqbal R; Coss E; Park C; Cryer B; Genta RM
Hum Pathol; 2013 Dec; 44(12):2706-10. PubMed ID: 24071014
[TBL] [Abstract][Full Text] [Related]
44. Proton Pump Inhibitors and Risk of Cardiovascular Disease: A Self-Controlled Case Series Study.
Park JY; Yoo J; Jeon J; Kim J; Kang S
Am J Gastroenterol; 2022 Jul; 117(7):1063-1071. PubMed ID: 35505518
[TBL] [Abstract][Full Text] [Related]
45. Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists and Risk of Pneumonia in Patients with Acute Stroke.
Momosaki R; Yasunaga H; Matsui H; Fushimi K; Abo M
J Stroke Cerebrovasc Dis; 2016 May; 25(5):1035-1040. PubMed ID: 26853142
[TBL] [Abstract][Full Text] [Related]
46. Proton pump inhibitors versus histamine-2 receptor blockers for stress ulcer prophylaxis in patients with sepsis: a retrospective cohort study.
Huang M; Han M; Han W; Kuang L
J Int Med Res; 2021 Jun; 49(6):3000605211025130. PubMed ID: 34182815
[TBL] [Abstract][Full Text] [Related]
47. Proton pump inhibitors and hospitalization with hypomagnesemia: a population-based case-control study.
Zipursky J; Macdonald EM; Hollands S; Gomes T; Mamdani MM; Paterson JM; Lathia N; Juurlink DN
PLoS Med; 2014 Sep; 11(9):e1001736. PubMed ID: 25268962
[TBL] [Abstract][Full Text] [Related]
48. Proton pump inhibitors and chronic kidney disease risk: a comparative study with histamine-2 receptor antagonists.
Kweon T; Kim Y; Lee KJ; Seo WW; Seo SI; Shin WG; Shin DH
Sci Rep; 2023 Dec; 13(1):21169. PubMed ID: 38036592
[TBL] [Abstract][Full Text] [Related]
49. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study.
Robertson DJ; Larsson H; Friis S; Pedersen L; Baron JA; Sørensen HT
Gastroenterology; 2007 Sep; 133(3):755-60. PubMed ID: 17678921
[TBL] [Abstract][Full Text] [Related]
50. Is use of a long-term proton pump inhibitor or histamine-2 receptor antagonist a risk factor for iron-deficiency anaemia in Taiwan? A neglected clinical drug-drug interaction.
Wu YT; Lu YT; Chu CY; Chao HJ; Kuo LN; Cheng KJ; Chen HY
Fam Pract; 2023 Sep; ():. PubMed ID: 37756627
[TBL] [Abstract][Full Text] [Related]
51. Proton pump inhibitor use represents an independent risk factor for myocardial infarction.
Shih CJ; Chen YT; Ou SM; Li SY; Chen TJ; Wang SJ
Int J Cardiol; 2014 Nov; 177(1):292-7. PubMed ID: 25499395
[TBL] [Abstract][Full Text] [Related]
52. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia.
Yin OQ; Giles FJ; Baccarani M; le Coutre P; Chiparus O; Gallagher N; Saglio G; Hughes TP; Hochhaus A; Kantarjian HM; Larson RA
Cancer Chemother Pharmacol; 2012 Aug; 70(2):345-50. PubMed ID: 22623211
[TBL] [Abstract][Full Text] [Related]
53. Use of proton pump inhibitors for the risk of gastric cancer.
Gao H; Li L; Geng K; Teng C; Chen Y; Chu F; Zhao Y
Medicine (Baltimore); 2022 Dec; 101(49):e32228. PubMed ID: 36626449
[TBL] [Abstract][Full Text] [Related]
54. The Association of Long-Term Use of Proton Pump Inhibitors and Histamine H
Gao J; Ma S; Xu S; Chen M
Dis Markers; 2022; 2022():4093595. PubMed ID: 35801003
[TBL] [Abstract][Full Text] [Related]
55. Association Between Proton Pump Inhibitor Use and Risk of Asthma in Children.
Wang YH; Wintzell V; Ludvigsson JF; Svanström H; Pasternak B
JAMA Pediatr; 2021 Apr; 175(4):394-403. PubMed ID: 33555324
[TBL] [Abstract][Full Text] [Related]
56. Proton pump inhibitors are associated with incident type 2 diabetes mellitus in a prospective population-based cohort study.
Czarniak P; Ahmadizar F; Hughes J; Parsons R; Kavousi M; Ikram M; Stricker BH
Br J Clin Pharmacol; 2022 Jun; 88(6):2718-2726. PubMed ID: 34907592
[TBL] [Abstract][Full Text] [Related]
57. Systematic review with meta-analysis: the risks of proton pump inhibitors during pregnancy.
Li CM; Zhernakova A; Engstrand L; Wijmenga C; Brusselaers N
Aliment Pharmacol Ther; 2020 Feb; 51(4):410-420. PubMed ID: 31909512
[TBL] [Abstract][Full Text] [Related]
58. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study.
Poulsen AH; Christensen S; McLaughlin JK; Thomsen RW; Sørensen HT; Olsen JH; Friis S
Br J Cancer; 2009 May; 100(9):1503-7. PubMed ID: 19352380
[TBL] [Abstract][Full Text] [Related]
59. Safety of Concomitant Metformin and Proton Pump Inhibitor Use: A Population Retrospective Cohort Study.
Chen CB; Lin M; Eurich DT; Johnson JA
Clin Ther; 2016 Jun; 38(6):1392-1400. PubMed ID: 27061884
[TBL] [Abstract][Full Text] [Related]
60. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study.
Park JH; Song YM; Jung JH; Han K
Bone; 2020 Jun; 135():115306. PubMed ID: 32126312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
